ICU sedation, delirium & recovery
Association of Dexmedetomidine With New-Onset Atrial Fibrillation in Patients With Critical Illness
Main findingResult — go to the resultHazard ratio 0.80 95% CI 0.71–0.90Authors' conclusion
This study found that dexmedetomidine was associated with decreased risk of NOAF in patients with critical illness
Study context
- Population
- Adults (≥18 years) hospitalized in the intensive care unit (ICU), Beth Israel Deaconess Medical Center, Boston, 2008–2019 (MIMIC-IV database)matched cohort
- Participants
- 8,015 adults
- Exposure
- Dexmedetomidine within 48 h of ICU admission vs no dexmedetomidine
- Dexmedetomidinen = 2,106
- No dexmedetomidinen = 5,909reference
- Outcome
- New-onset atrial fibrillation (NOAF), by nurse-recorded rhythm status
- Follow-up
- Within 7 days of ICU admission
Methodological detailspropensity score-matched, 1:3 matching, single-centre database (MIMIC-IV)
- Propensity score-matched
- 1:3 matching
- Single-centre database (MIMIC-IV)
Main finding
As reported in the abstract
Hazard ratio
0.80
95% CI 0.71–0.90
Events by group
Dexmedetomidine vs No dexmedetomidine
HR 0.80 (95% CI 0.71–0.90)
Observational data: associations, not effects.
Secondary outcomes
ICU LOS
P < 0.001
Hospital LOS
P < 0.001
| Outcome | Dexmedetomidine | No dexmedetomidine | HR (95% CI) | |
|---|---|---|---|---|
| In-hospital mortality | 6.3% | 12.8% | 0.43 (0.36–0.52) | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Association of Dexmedetomidine With New-Onset Atrial Fibrillation in Patients With Critical Illness. JAMA Netw Open. Published 3 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →